

A transdermal delivery system comprising: 1. an ethoxylated lipid;

an alcohol mixed with the ethoxylated lipid so as to form a penetration enhancer;

an aqueous adjuvant mixed with the penetration enhancer, wherein the aqueous adjuvant is a plant extract from the family of Liliaceae; and

a delivery agent mixed with the aqueous adjuvant and the penetration enhancer.

- 2. The transdermal delivery system of a Claim 1, wherein the ethoxylated lipid is a vegetable/or animal oil having at least 20 ethoxylations per molecule.
- The transdermal delivery system of Claim 1, wherein about 0.1% to 3. 40.0% by weight or volume is ethoxylated lipid.
- The transdermal delivery system of Claim 1, wherein about 0.1% to 15% by weight or volume is alcohol.
- The transdermal delivery system of Claim 1, wherein about 0.1% to 85% by weight or volume is Aloe Vera.
- The transdermal delivery system of Claim 1, wherein the ratio of 6. ethoxylated lipid:alcohol:aqueous adjuvant is selected from the group consisting of 1:1:4, 1:1:14, 3:4:3, and 1:10:25.
- The transdermal delivery system of Claim 1, wherein the delivery agent 7. is a molecule having a molecular weight of less than 6,000 daltons.
- The transdermal delivery system of Claim 1, wherein the delivery agent 8. is a molecule having a molecular weight of greater than 6,000 daltons.
- The transdermal delivery system of Claim 1, wherein the delivery agent 9. is one or more of the compounds/selected from the group consisting of capsaicin, Boswellin, non steroidal anti-inflammatory drug, and collagen.
- An apparatus comprising a vessel joined to an applicator and the 10. transdermal delivery system of Claim 1 incorporated in the vessel.
- The apparatus of Claim 10, wherein the applicator is a roll-on or a 11. sprayer.

10

ij

The core compared of the South State State & South & State & S

20

30



5

10

15

The state of the s

think their are are

:3

25 Sub

30

12. A transdermal delivery system comprising: an ethoxylated oil;

an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;

an Aloe extract mixed with the penetration enhancer; and
a therapeutically effective amount of capsaicin or NSAID or both
mixed with the penetration enhancer and Aloe extract.

The transdermal delivery system of Claim 12, wherein the therapeutically effective amount of capsaicin is by weight or volume 0.01% to 5.0% capsaicin or 1.0% to 13% oleoresin capsicum.

The transdermal delivery system of Claim 12, further comprising by weight or volume 0.1% to 10% Boswellin.

An apparatus comprising a ressel joined to an applicator and the transdermal delivery system of Claim 2 incorporated in the vessel.

The apparatus of Claim 15, wherein the applicator is a roll-on or a sprayer.

17. A method of reducing pain or inflammation comprising the step of administering the transdermal delivery system of Claim 12 to a subject in need and monitoring the reduction in pain or inflammation.

18. A method of treating or preventing cancer and Alzheimer's disease comprising the step of identifying a subject in need of a COX enzyme inhibitor and administering the transdermal delivery system of Claim 12 to the subject.

19. A transdermal delivery system comprising: an ethoxylated oil;

an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;

an aqueous adjuvant mixed with the penetration enhancer; and a therapeutically effective amount of a delivery agent having a molecular weight of more than 6,000 mixed with the penetration enhancer and aqueous adjuvant.



10



20. The transdermal delivery system of Claim 19, wherein the aqueous adjuvant is derived from Aloe.

21. The transdermal delivery system of Claim 19 wherein the delivery agent is collagen.

22. The transdermal delivery system of Claim 20, wherein the collagen has an approximate average molecular weight from about 300,000 daltons to about 500,000 daltons.

23. The transdermal delivery system of Claim 20, wherein the therapeutically effective amount of collagen by weight or volume is 0.1% to 50.0%.

24. The transdermal delivery system of Claim 20, wherein the collagen is Hydrocoll EN-55 and the therapeutically effective amount by weight or volume is 0.1% to 50.0%.

25. The transdermal delivery system of Claim 20, wherein the collagen is Solu-Coll and the therapeutically effective amount is 0.1% to 2.0%.

26. The transfermal delivery system of Claim 20, wherein the collagen is Plantsol and the therapeutically effective amount by weight or volume is 0.1% to 4.0%.

An apparatus comprising a vessel joined to an applicator and the transdermal delivery system of Claim 19 incorporated in the vessel.

3628. The apparatus of Claim 271, wherein the applicator is a roll-on or a sprayer.

29. A method of reducing wrinkles in the skin comprising: identifying a subject in need of skin tone restoration;

administering a transdermal delivery/system to the subject, wherein the transdermal delivery system comprises:

an ethoxylated oil;

an alcohol mixed with the ethoxylated oil so as to form a penetration enhancer;

Aloe extract mixed with the penetration enhancer; and

a therapeutically effective amount of collagen mixed with the penetration enhancer and aqueous adjuvant;

30

25





5

10

and monitoring the restoration of skin tone.

30. A method of making a transdermal delivery system comprising: providing an ethoxylated oil;

mixing the ethoxylated oil with an alcohol, nonionic solubilizer, or emulsifier so as to form a penetration enhancer;

mixing the penetration enhancer with an aqueous adjuvant, wherein the aqueous adjuvant is an extract from a plant of the Liliaeacae family; and

mixing the penetration enhancer and aqueous adjuvant with a delivery agent and thereby making the transdermal delivery system.

The method of Claim 30, wherein the delivery agent is selected from the group consisting of capsaicin, Boswellin, non steroidal anti-inflammatory drug, and collagen.

32. The method of Claim 30, wherein the delivery agent has a molecular weight greater than 6,000 daltons.

4433. The method of Claim 36, further comprising incorporating the transdermal delivery system into an application device.

The method of Claim 32, wherein the application device has a roll-on applicator or a sprayer.

15 Sup

20

And there is a start that the start the start that the start that

add 85)